2023
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2020
Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa RA, Ma X. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2343-2350. PMID: 32868318, PMCID: PMC8895351, DOI: 10.1158/1055-9965.epi-20-0592.Peer-Reviewed Original ResearchConceptsRisk of MPNPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsHazard ratioSugar intakeDietary factorsMultivariable Cox proportional hazards modelsRisk of PVCox proportional hazards modelHigh sugar intakeNIH-AARP DietIntake of fatConfidence intervalsNIH-AARP cohortRole of dietProportional hazards modelPotential confounding variablesParticipants ages 50Warrants further investigationProspective cohortHigh intakePV riskAge 50Health StudyEpidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsClassical myeloproliferative neoplasmsPrimary myelofibrosisIncidence of CMLEnd Results program dataTyrosine kinase inhibitor therapyCML patient outcomesClonal myeloid disordersKinase inhibitor therapyPotential etiological roleInhibitor therapyMale genderRisk factorsPatient outcomesMyeloid leukemiaPMF patientsBetter survivalGeneral populationEtiological roleMyeloid disordersMolecular abnormalitiesEpidemiological literatureLifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.Peer-Reviewed Original ResearchConceptsNIH-AARP DietPolycythemia veraMyeloproliferative neoplasmsEssential thrombocythemiaHazard ratioLifestyle factorsCaffeine intakeHealth StudyMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRisk of PVProportional hazards regression modelsRisk of MPNLarge prospective studiesHazards regression modelsConfidence intervalsPhiladelphia chromosome-negative myeloproliferative neoplasmsMPN riskOverall cohortProspective cohortProspective studyInverse associationRisk factorsPV riskProtective effect
2018
Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study
Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood 2018, 132: 3580. DOI: 10.1182/blood-2018-99-119272.Peer-Reviewed Original ResearchStatin usersImpact of statinsLog-rank testRisk of thrombosisOverall survivalPercentage of daysPV patientsMyeloproliferative neoplasmsPV diagnosisMultivariate Cox proportional hazards modelContinuous Medicare Parts ACox proportional hazards modelCardiovascular risk factorsEnd Results-MedicareErythropoietin-independent erythroid colony formationBetter overall survivalKaplan-Meier curvesType of statinPopulation-based cohortNumber of phlebotomiesEnd of studyProportional hazards modelPart DMedicare Part AHealth maintenance organization
2016
Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer 2016, 16: 167. PMID: 26922064, PMCID: PMC4769833, DOI: 10.1186/s12885-016-2208-2.Peer-Reviewed Original ResearchConceptsPrognostic risk scoreMyeloproliferative neoplasmsRisk scorePolycythemia veraEssential thrombocythemiaDisease burdenDaily livingOverall healthSymptom severityMedian disease durationLandmark surveyPatient's overall healthOverall disease burdenRisk of mortalityMedian respondent ageLower symptom severityDisease durationSymptom burdenPatients' qualityMPN subtypesTreatment managementPatientsConclusionsThese findingsResultsThe surveyQoL
2014
Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY
Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski D, Boyle J, Mascarenhas J. Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY. Blood 2014, 124: 4827. DOI: 10.1182/blood.v124.21.4827.4827.Peer-Reviewed Original ResearchPatient-physician communicationIncyte CorporationPrognostic risk scoreImportant treatment goalMost patientsDisease burdenMajority of physiciansTreatment goalsMyeloproliferative neoplasmsPolycythemia veraEssential thrombocythemiaPrognostic riskPhysicians' perceptionsSpeakers bureauRisk scoreDisease settingsPoor patient-physician communicationFourth of patientsPrimary treatment recommendationLandmark surveyThird of patientsOverall managementDisease-related symptomsAdvisory CommitteeYears of ageImpact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States
Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski D, Boyle J, Mascarenhas J. Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States. Blood 2014, 124: 3183. DOI: 10.1182/blood.v124.21.3183.3183.Peer-Reviewed Original ResearchPrognostic risk scoreMajority of patientsIncyte CorporationLow-risk scoresRisk scoreMyeloproliferative neoplasmsEssential thrombocythemiaOverall healthSymptom burdenDays of workSpeakers bureauPolycythemia veraSignificant burdenSubset of patientsTotal symptom scoreImpact of symptomsAdvisory CommitteeHigh-risk scoreChronic myeloproliferative neoplasmsNovartis Pharmaceuticals CorporationQuality of lifeLandmark surveyMarked burdenEligible patientsSymptom scores